Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 10—October 2022

SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA

Alexander C. KeyelComments to Author , Alexis Russell, Jonathan Plitnick, Jemma V. Rowlands, Daryl M. Lamson, Eli Rosenberg, and Kirsten St. George
Author affiliations: New York State Department of Health, Albany, New York, USA (A.C. Keyel, A. Russell, J. Plitnick, J.V. Rowlands, D.M. Lamson, E. Rosenberg, K. St. George); State University of New York, Albany (E. Rosenberg, K. St. George)

Main Article

Table 2

Variables most associated with an Omicron variant in 3 analyses of SARS-CoV-2 vaccine breakthrough during the emergence period of the Omicron variant, New York, USA*

Model ΔAIC Odds ratio (95% CI)
Parameter 1 Parameter 2 Parameter 3
Main analysis
Vaccination status 0 Vaccinated: 
3.1 (2.0–4.9)† Vaccinated + boosted: 6.7 (3.4–13.0)†
Vaccine type 3.33 Pfizer Moderna Janssen
Without booster 3.3 (1.9–5.6)† 3.6 (2.0–6.7)† 2.0 (0.8–5.1)
With booster

10.4 (4.3–25.2)†
3.8 (1.5–9.3)‡

Age analysis
Vaccination status + age
+ age groups 0.00 Vaccinated: 
4.8 (2.8–8.1)† Vaccinated + boosted: 38.5 (15.9–93.2)† Age, linear: 0.964 (0.950–0.978);† age 0–4 y: 0.250 (0.059–1.051); age 18–29 y: 2.0 (1.1–3.7)§
Vaccination status + age
5.0 (3.0–8.3)†
Vaccinated + boosted: 34.1 (14.6–79.5)†
Age: 0.962 (0.950–0.974)†
Vaccination-only analysis
Janssen + days after dose 0.00 Janssen, relative to mRNA vaccine: 
0.388 (0.149–1.009) Days after last dose, booster or primary series: 0.996 (0.993–0.999)‡
Vaccine type + days after dose 1.18 Moderna, relative to Pfizer: 
0.776 (0.448–1.344) Janssen, relative to Pfizer: 
0.351 (0.132–0.935)§ Days after last dose, booster or primary series:0.996 (0.993–0.999)‡

*Only 1 boosted person had received an initial dose of Janssen vaccine, so for statistical reasons, this person was pooled with the unboosted Janssen recipients. When fit separately, the odds ratio for unboosted Janssen recipients was 1.9 (0.8–4.9) with a parameter p value of 0.20, and the parameter estimate for the single boosted Janssen individual was unreliable. Janssen vaccine, Janssen/Johnson & Johnson (; Pfizer vaccine, Pfizer-BioNTech (; Moderna vaccine, Moderna ( ΔAIC, change in Akaike information criterion. †p<0.001. ‡p<0.01. §p<0.05.

Main Article

Page created: August 25, 2022
Page updated: September 20, 2022
Page reviewed: September 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.